Synendos receives EMA nod for brain therapy
Company is focused on endocannabinoid system treatments
Read Moreby John Pinching | Jan 18, 2024 | News | 0
Company is focused on endocannabinoid system treatments
Read Moreby John Pinching | Jul 24, 2023 | News | 0
The drug is an injectable or tablet specifically developed for HIV prevention among certain individuals
Read Moreby John Pinching | Jul 20, 2023 | News | 0
In two studies the therapy demonstrated improvements when compared with the placebo
Read Moreby John Pinching | Dec 2, 2022 | News | 0
Positive scientific opinion by EMA would create pathway for arpraziquantel in African endemic countries
Read Moreby Fleur Jeffries | Aug 23, 2022 | News | 0
Despite current treatments, the mortality rate for patients with invasive candidiasis remains high
Read Moreby John Pinching | Jul 18, 2022 | News | 0
The submission follows positive results of phase 3 trial focusing on breast cancer therapy
Read Moreby John Pinching | Mar 8, 2022 | News | 0
Advanced Therapy Medicinal Product classification for Ixaka Ltd’s chemically encapsulated lentiviral vector
Read Moreby John Pinching | Feb 25, 2022 | News | 0
Valneva expects to receive a positive CHMP recommendation for the conditional approval of its VLA2001 vaccine
Read Moreby PharmaTimes | Nov 25, 2021 | News | 0
The use of molnupiravir in COVID-19 cases aims to reduce the pressure on hospitals, in turn reducing the risk of patients developing more severe symptoms of the virus.
Read Moreby Lucy Parsons | Nov 15, 2021 | News | 0
Those eligible will have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
Read Moreby Lucy Parsons | Jul 27, 2021 | News | 0
Study in adolescents met it primary endpoint, successfully bridging immune responses to those observed in an efficacy study in adults
Read Moreby Lucy Parsons | May 25, 2021 | News | 0
CHMP recommended EU approval for combination treatment in its May decisions
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479